CAR-T Meets LNP: A Familiar Platform with a New CMC Challenge

Two weeks ago, we wrote about mRNA and LNP platform industrialization and the evolution from pandemic urgency to sustainable and scalable manufacturing guidelines. However, the delivery systems at the center of that article, LNPs and engineered viral vectors, are also appearing in another, different context: in-vivo CAR-T therapy where they are the manufactured product themselves.

Notably, formulation science, particle characterization methods, and GMP infrastructure being built for mRNA therapeutics are foundations very similar to those any in-vivo CAR-T program will depend on. This means that the CMC teams working in one program are relevant to the other. 

However, significantly for CMC, in-vivo CAR-T therapy eliminates the known complexities of conventional autologous therapies: no patient-specific manufacturing cycle, no apheresis, ex-vivo T-cell isolation, activation, expansion or cryopreservation. Instead, the viral vector or LNP carrying the CAR gene is manufactured under GMP conditions, administered directly, and the patient’s own T cells are reprogrammed in the body. A May, 2026 perspective in Nature Signal Transduction and Targeted Therapy estimates a 1.5 to 3-week reduction in manufacturing time, with projected cost reductions of 50% or more per treatment course, compared to traditional CAR-T. Reassuringly, first-in-human clinical data now exists for both lentiviral vector and LNP-based platforms. That said, while in-vivo approaches eliminate ex-vivo cell processing complexity, they introduce new CMC demands on the delivery vector.

Batch-to-batch consistency for viral vectors remains technically demanding. Still, two CMC gaps are particularly active at this stage: comparability strategies for in-vivo products are not yet established, and when manufacturing changes occur, which they will, the field will not yet have a standard framework for what adequate comparability data looks like for these modalities. Separately, according to Lu et al., novel analytical methods are needed to assess transduction efficiency, T-cell specificity, and potency in a system in which cells are generated within the patient rather than in a bioreactor. Programs that arrive at these gaps late will face the same friction that slowed early ex-vivo CGT development.

At Pharmefex, we have deep practical industry knowledge in viral and non-viral gene delivery, in addition to CAR-T therapy. Our team can provide technical support, or CMC and regulatory support for developing in-vivo CAR-T programs. With experience in viral vectors and LNP modalities, we have the breadth of industry experience, the knowledge to predict development bottlenecks, and the ability to smooth CDMO management. 

Manufacturing simplicity is a compelling argument for in-vivo CAR-T. To ensure success, it is required that the manufacturing, analytical, and regulatory groundwork is laid before it is needed, not the standard we’ll engage later.

#CellTherapy #GeneTherapy #CART #CARTcell #InVivoCART #CMC #LNP #ViralVectors #Biotech #Pharma #DrugDevelopment #RegulatoryStrategy #Manufacturing #Pharmefex #Dahliaconsulting

Sources

Primary Source:  Lu et al. — The In-vivo Revolution in CAR-T Therapy Medicinal Products: Challenges and Regulatory Prospects Nature Signal Transduction and Targeted Therapy, Vol. 11, Article 192 (May 22, 2026).

https://www.nature.com/articles/s41392-026-02633-4

Additional Sources: 

BioInsights, Cell and Gene Therapy Insights 2026 https://www.insights.bio/cell-and-gene-therapy-insights/spotlights/year/2026

FDA: RMAT Designation (Regenerative Medicine Advanced Therapy) https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/regenerative-medicine-advanced-therapy-designation

ICH Cell and Gene Therapy Discussion Group (CGTDG) https://www.ich.org/page/cell-gene-therapy-discussion-group